Comparison of cobasEGFRMutation Test v2 and PANAMutyper-R-EGFRfor Detection and Semi-Quantification of Epidermal Growth Factor Receptor Mutations in Plasma and Pleural Effusion Supernatant-Reference-Cited by-同舟云学术

Comparison of cobasEGFRMutation Test v2 and PANAMutyper-R-EGFRfor Detection and Semi-Quantification of Epidermal Growth Factor Receptor Mutations in Plasma and Pleural Effusion Supernatant

Published:2019-09-01 Issue:5 Volume:39 Page:478-487
ISSN:2234-3806
Container-title:Annals of Laboratory Medicine
language:en
Short-container-title:Ann Lab Med

Author:

Han A-Lum¹^ORCID,Kim Hak-Ryul²^ORCID,Choi Keum-Ha³^ORCID,Hwang Ki-Eun²^ORCID,Zhu Mengyu⁴^ORCID,Huang Yuya⁴^ORCID,Wu Moxin⁴^ORCID,Lee Young-Jin⁴^ORCID,Park Min-Cheol⁵^ORCID,Cho Ji-Hyun⁴^ORCID,Park Do-Sim⁴⁶^ORCID

Affiliation:

1. Department of Family Medicine, School of Medicine, Wonkwang University, Iksan, Korea

2. Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Korea

3. Department of Pathology, School of Medicine, Wonkwang University, Iksan, Korea

4. Department of Laboratory Medicine and Institute of Wonkwang Medical Science, School of Medicine, Wonkwang University, Iksan, Korea

5. Department of Oriental Medical Ophthalmology & Otolaryngology & Dermatology, College of Oriental Medicine, Wonkwang University, Iksan, Korea

6. Wonkwang Institute of Clinical Medicine, Wonkwang University Hospital, Iksan, Korea

Funder

Wonkwang University Hospital Biobank

National Research Foundation of Korea

Publisher

Annals of Laboratory Medicine

Subject

Biochemistry (medical),Clinical Biochemistry,General Medicine

Link

https://synapse.koreamed.org/pdf/10.3343/alm.2019.39.5.478

Reference25 articles.

1. Epidermal growth factor receptor mutations in lung cancer

2. Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

3. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

4. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

5. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Minimally Invasive, Maximally Effective;Surgical Pathology Clinics;2024-09

2. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

3. Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations;Genes;2023-06-02

4. The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer;Life;2022-10-19

5. Effects of Different Centrifugation Protocols on the Detection of EGFR Mutations in Plasma Cell-Free DNA;American Journal of Clinical Pathology;2022-03-14